• Publications
  • Influence
Heart failure: evaluation and care of patients with left ventricular systolic dysfunction.
  • 492
  • 14
Swift Monitoring of NGC 4151: Evidence for a Second X-Ray/UV Reprocessing
NASA [NNX13AC26G, NNX13AC63G, NNX13AE99G, NNH13CH61C]; NSF [AST-1412693, AST-1253702, AST-1211916, AST-1009571, AST-1210311, AST-1412315]; STFC [ST/M001296/1]; National Research Foundation (NRF) ofExpand
  • 51
  • 9
  • PDF
A clinician's guide to statin drug-drug interactions.
The statins are widely used worldwide to reduce risk for cardiovascular events in both the primary and secondary prevention settings. Although generally quite safe, the statins can be associated withExpand
  • 80
  • 5
Labetalol pharmacokinetics and pharmacodynamics: Evidence of stereoselective disposition
Labetalol pharmacokinetics and pharmacodynamics were evaluated in nine subjects before and during enzyme inhibition with Cimetidine. Pharmacologic response was assessed by use of standardizedExpand
  • 32
  • 4
Statin safety and drug interactions: clinical implications.
  • M. Bottorff
  • Medicine
  • The American journal of cardiology
  • 17 April 2006
The risks of muscle adverse events related to use of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, increase significantly with the addition of interactingExpand
  • 176
  • 4
Thrombotic Events Associated with C1 Esterase Inhibitor Products in Patients with Hereditary Angioedema: Investigation from the United States Food and Drug Administration Adverse Event Reporting
To investigate reports of thrombotic events associated with the use of C1 esterase inhibitor products in patients with hereditary angioedema in the United States.
  • 58
  • 2
Antiplatelet Therapy in Patients with Unstable Angina and Non–ST‐Segment‐Elevation Myocardial Infarction: Findings from the CRUSADE National Quality Improvement Initiative
Evidence‐based clinical practice guidelines encapsulate current knowledge to guide health care professionals in the treatment of patients with unstable angina or non–ST‐segment‐elevation myocardialExpand
  • 28
  • 2
Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians.
The hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors (HMGs) have an excellent safety profile. 1,2 Each of the 6 members of this therapeutic class (lovastatin, 3 simvastatin, 4Expand
  • 122
  • 1
  • PDF
Mechanism of antiarrhythmic drug-induced changes in defibrillation threshold: role of potassium and sodium channel conductance.
OBJECTIVES We sought to determine which ion current predominantly affects defibrillation outcomes by using specific pharmacologic probes (lidocaine [a sodium channel blocking agent] and cesium [anExpand
  • 29
  • 1
Pharmacokinetics of Eprosartan in Healthy Subjects, Patients with Hypertension, and Special Populations
After oral administration of eprosartan to healthy volunteers, bioavailability is approximately 13%, with peak plasma concentrations occurring 1–2 hours after an oral dose in the fasted state. FoodExpand
  • 23
  • 1